دورية أكاديمية
Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study.
| العنوان: | Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study. |
|---|---|
| المؤلفون: | Atalay S; Department of Dermatology, Radboud university medical center, 6525 Nijmegen, The Netherlands. E-mail: selma.atalay@radboudumc.nl., van den Reek JMPA, Otero ME, Njoo MD, Mommers JM, Ossenkoppele PM, Koetsier MI, Berends MM, van de Kerkhof PCM, Groenewoud HMM, den Broeder AA, de Jong EMGJ, Kievit W |
| المصدر: | Acta dermato-venereologica [Acta Derm Venereol] 2020 Dec 01; Vol. 100 (19), pp. adv00340. Date of Electronic Publication: 2020 Dec 01. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MJS Publishing Country of Publication: Sweden NLM ID: 0370310 Publication Model: Electronic Cited Medium: Internet ISSN: 1651-2057 (Electronic) Linking ISSN: 00015555 NLM ISO Abbreviation: Acta Derm Venereol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2024- : Uppsala, Sweden : MJS Publishing Original Publication: Stockholm : Acta dermato-venereologica |
| مواضيع طبية MeSH: | Psoriasis*/diagnosis , Psoriasis*/drug therapy , Ustekinumab*/adverse effects, Adalimumab/adverse effects ; Cost-Benefit Analysis ; Drug Tapering ; Etanercept/adverse effects ; Humans ; Quality of Life |
| مستخلص: | A dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis who have stable and low disease activity has recently been compared with usual care in the CONDOR study (CONtrolled DOse Reduction) of biologics in patients with psoriasis with low disease activity. The aim of the current study was to perform a cost-utility analysis with a 12-month time horizon alongside this trial, using prospectively measured healthcare costs and quality-adjusted life years, based on Short-Form Six-Dimension utilities. Bootstrap analys-es were used to calculate the decremental cost-utility ratio and the incremental net monetary benefit. The dose reduction strategy resulted in a mean cost saving of €3,820 (95th percentile -€3,099 to -€4,509) per patient over a period of 12 months. There was an 83% chance that dose reduction would result in a reduction in quality adjusted life years (mean -0.02 (95th percentile -0.06 to 0.02). In conclusion, dose reduction of biologics resulted in substantial cost savings with an acceptable reduction in quality of life. |
| References: | BMC Dermatol. 2017 May 8;17(1):6. (PMID: 28482858) Cutis. 2017 Dec;100(6):405-410. (PMID: 29360888) BMJ. 2015 Apr 09;350:h1389. (PMID: 25858265) JAMA Dermatol. 2020 Apr 1;156(4):393-400. (PMID: 32049319) J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1444-7. (PMID: 22702802) Int J Mol Sci. 2017 Nov 01;18(11):. (PMID: 29104241) Ann Rheum Dis. 2009 Jul;68(7):1177-83. (PMID: 19019889) Ann Rheum Dis. 2016 Nov;75(11):1939-1944. (PMID: 26764260) Lancet. 2015 Jul 18;386(9990):258-65. (PMID: 25975452) PLoS One. 2017 Nov 9;12(11):e0187477. (PMID: 29121647) Ther Drug Monit. 2017 Aug;39(4):379-386. (PMID: 28570371) Lancet. 2007 Jul 21;370(9583):263-271. (PMID: 17658397) Clin Rev Allergy Immunol. 2018 Feb;54(1):102-113. (PMID: 29349534) Qual Life Res. 2019 Sep;28(9):2373-2381. (PMID: 30945132) JAMA. 2006 May 17;295(19):2275-85. (PMID: 16705109) J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1523-1529. (PMID: 29524271) Ann Rheum Dis. 2019 Jan;78(1):141-142. (PMID: 30150367) Value Health. 2017 Apr;20(4):577-585. (PMID: 28407999) J Manag Care Spec Pharm. 2018 Dec 17;:1-11. (PMID: 30556761) Med Care. 1992 Jun;30(6):473-83. (PMID: 1593914) J Am Acad Dermatol. 2018 Feb;78(2):406-408. (PMID: 29332710) Br J Dermatol. 2018 Jan;178(1):103-113. (PMID: 28722163) J Dermatol. 2008 Aug;35(8):484-90. (PMID: 18789067) Front Immunol. 2018 Aug 13;9:1668. (PMID: 30150978) Actas Dermosifiliogr. 2015 Sep;106(7):569-77. (PMID: 25935194) |
| فهرسة مساهمة: | Keywords: CONDOR study; biologics; cost-utility; dose reduction strategy; psoriasis |
| المشرفين على المادة: | FU77B4U5Z0 (Ustekinumab) FYS6T7F842 (Adalimumab) OP401G7OJC (Etanercept) |
| تواريخ الأحداث: | Date Created: 20201116 Date Completed: 20210623 Latest Revision: 20221021 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9309701 |
| DOI: | 10.2340/00015555-3692 |
| PMID: | 33196101 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1651-2057 |
|---|---|
| DOI: | 10.2340/00015555-3692 |